NCT00105950 - Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer | Biotech Hunter

Enrollment

126

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

September 30, 2007

Study Completion Date

May 31, 2010

Conditions

Neoplasms, Breast

Interventions

DRUG

lapatinib

Tyrosine kinase inhibitor administered daily at 1500 mg/kg

Trial Locations (27)

1000

GSK Investigational Site, Brussels

1004

GSK Investigational Site, Tunis

1007

GSK Investigational Site, Tunis

3000

GSK Investigational Site, Sfax

3029

GSK Investigational Site, Sfax

13273

GSK Investigational Site, Marseille

17007

GSK Investigational Site, Girona

27710

GSK Investigational Site, Durham

28041

GSK Investigational Site, Madrid

44805

GSK Investigational Site, Saint-Herblain

48201

GSK Investigational Site, Detroit

52621

GSK Investigational Site, Ramat Gan

60099

GSK Investigational Site, Zion

60637

GSK Investigational Site, Chicago

63110

GSK Investigational Site, St Louis

64100

GSK Investigational Site, Bayonne

69373

GSK Investigational Site, Lyon

70300

GSK Investigational Site, Zrifin

75248

GSK Investigational Site, Paris

75970

GSK Investigational Site, Paris

98109

GSK Investigational Site, Seattle

33136-1002

GSK Investigational Site, Miami

20892-1201

GSK Investigational Site, Bethesda

M4N 3M5

GSK Investigational Site, Toronto

08035

GSK Investigational Site, Barcelona

08036

GSK Investigational Site, Barcelona

SW3 6JJ

GSK Investigational Site, London